Lilly’s verzenio data shows decrease in breast cancer recurrence

 

• Eli Lilly (LLY +4.2%) has reported additional data from a pre-planned primary outcome analysis from Phase 3 monarchE trial evaluating Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET), for breast cancer. Data were presented at the Virtual San Antonio Breast Cancer Symposium.
• The study showed that Verzenio decreased the risk of breast cancer recurrence by 28.7% compared to standard adjuvant ET alone. This statistically significant improvement corresponds to a 3% difference in the two-year rate of invasive disease-free survival between arms (92.3% in Verzenio arm vs. 89.3%)
• Lilly will submit trial data to regulatory authorities by the end of this year.
• Earlier today, the company reported that tirzepatide showed significant A1C and weight reductions in patients with type 2 diabetes.
• https://seekingalpha.com/news/3642951-lilly-s-verzenio-data-shows-decrease-in-breast-cancer-recurrence